Tella Inc
TSE:2191
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
Tella Inc
Net Income
Tella Inc
Net Income Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Net Income | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Tella Inc
TSE:2191
|
Net Income
-¥945.6m
|
CAGR 3-Years
-1%
|
CAGR 5-Years
-2%
|
CAGR 10-Years
N/A
|
|
|
Carna Biosciences Inc
TSE:4572
|
Net Income
-¥2.2B
|
CAGR 3-Years
-18%
|
CAGR 5-Years
-14%
|
CAGR 10-Years
N/A
|
|
|
S
|
Shin Nippon Biomedical Laboratories Ltd
TSE:2395
|
Net Income
¥5.6B
|
CAGR 3-Years
-18%
|
CAGR 5-Years
12%
|
CAGR 10-Years
9%
|
|
|
Medinet Co Ltd
TSE:2370
|
Net Income
-¥1.4B
|
CAGR 3-Years
-3%
|
CAGR 5-Years
-10%
|
CAGR 10-Years
2%
|
|
|
Immuno-Biological Laboratories Co Ltd
TSE:4570
|
Net Income
¥295.5m
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
D
|
DNA Chip Research Inc
TSE:2397
|
Net Income
-¥55.4m
|
CAGR 3-Years
25%
|
CAGR 5-Years
15%
|
CAGR 10-Years
9%
|
|
Tella Inc
Glance View
tella, Inc. engages in research and development of dendritic cell (DC) vaccine therapy. The company is headquartered in Shinjuku, Tokyo-To and currently employs 30 full-time employees. The company went IPO on 2009-03-26. The firm operates through three business segments. The Cell Medicine segment is engaged in the provision of cancer treatment technology and operational method centered on dendritic cell vaccine therapy. This segment is also engaged in the provision of Services for contract medical institutions, such as cell culture system maintenance support services, management system maintenance support services and disease support services. The Medical Support segment is mainly engaged in the provision of drug development services (CROs) and genetic testing services. The Pharmaceutical segment is engaged in the development of the dendritic cell vaccine for regulatory approval as a product for cancer regenerative medicine.
See Also
What is Tella Inc's Net Income?
Net Income
-945.6m
JPY
Based on the financial report for Mar 31, 2022, Tella Inc's Net Income amounts to -945.6m JPY.
What is Tella Inc's Net Income growth rate?
Net Income CAGR 5Y
-2%
Over the last year, the Net Income growth was 11%. The average annual Net Income growth rates for Tella Inc have been -1% over the past three years , -2% over the past five years .
